Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1005-1007. doi: 10.1051/medsci/2019199. Epub 2020 Jan 6.

[Monoclonal antibodies in neurology].

[Article in French; Abstract available in French from the publisher]

Author information

Université de Tours, Inserm U1253, laboratoire de biochimie, CHRU de Tours, France.
Département des Maladies du Système Nerveux, Centre Référent Maladie Rare SLA, Hôpital de la Pitié-Salpétrière, Paris, France - Sorbonne Université, UPMC Univ Paris 6, CNRS, Inserm, laboratoire d'imagerie biomédicale, Paris, France.


in English, French

Therapeutic antibodies have been successfully developed in neurology. However, their efficacy needs to overcome a main hurdle that is their limited access to the brain. Moreover, the multifactorial characteristics of many neurological diseases complicate the identification of a specific target. In this review, we present the neuroroprotective effect of some monoclonal antibodies and we summarize how they can interact with neurodegenerative and inflammatory processes. Monoclonal antibodies, such as natalizumab, that represent a major achievement in multiple sclerosis, have been approved in this indication and used in the routine practice. Also, they are still in a phase of development in degenerative diseases and mainly aim to counteract the aggregation of misfolded proteins such as amyloid beta or tau proteins. Another strategy in development of new monoclonal antibodies is to block physiological inhibitors of axonal growth and myelination such as Nogo-A or its co-transporter LINGO-1. Finally, the recent approbation by the FDA of monoclonal antibodies against CGRP for migraine treatment has been a major breakthrough that expanded the potential fields of application of antibodies in neurology. Thus, a lot of research efforts are now devoted to improve the galenic forms, the routes of administration and to extend these various approaches to other targets.


Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center